Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Elevation Oncology, Inc. (ELEV) had Return on Tangible Equity of -30.41% for the most recently reported fiscal quarter, ending 2025-03-31.
Income Statement Financials | |
-- |
|
$-14.21M |
|
-- |
|
-- |
|
$14.22M |
|
$-14.22M |
|
$0.01M |
|
$-14.21M |
|
$-14.21M |
|
$-14.21M |
|
$-14.21M |
|
$-14.21M |
|
$-14.21M |
|
$-14.22M |
|
$-14.46M |
|
59.17M |
|
59.17M |
|
$-0.24 |
|
$-0.24 |
|
Balance Sheet Financials | |
$82.19M |
|
$0.03M |
|
$0.03M |
|
$82.22M |
|
$4.24M |
|
$31.25M |
|
$31.25M |
|
$35.49M |
|
$46.73M |
|
$46.73M |
|
$46.73M |
|
59.22M |
|
Cash Flow Statement Financials | |
$-12.71M |
|
$23.76M |
|
$-0.02M |
|
$49.46M |
|
$60.49M |
|
$11.03M |
|
$0.99M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
19.40 |
|
-- |
|
-- |
|
0.40 |
|
0.67 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.71M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-30.41% |
|
Return on Tangible Equity |
-30.41% |
-17.28% |
|
-18.22% |
|
$0.79 |
|
$-0.21 |
|
$-0.21 |